219 related articles for article (PubMed ID: 23798432)
21. Testosterone signals through mTOR and androgen receptor to induce muscle hypertrophy.
Basualto-Alarcón C; Jorquera G; Altamirano F; Jaimovich E; Estrada M
Med Sci Sports Exerc; 2013 Sep; 45(9):1712-20. PubMed ID: 23470307
[TBL] [Abstract][Full Text] [Related]
22. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells.
MacManus CF; Pettigrew J; Seaton A; Wilson C; Maxwell PJ; Berlingeri S; Purcell C; McGurk M; Johnston PG; Waugh DJ
Mol Cancer Res; 2007 Jul; 5(7):737-48. PubMed ID: 17606477
[TBL] [Abstract][Full Text] [Related]
24. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
25. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
Cai F; Zhang Y; Li J; Huang S; Gao R
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.
Wang Z; Wang Z; Guo J; Li Y; Bavarva JH; Qian C; Brahimi-Horn MC; Tan D; Liu W
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3053-8. PubMed ID: 22315407
[TBL] [Abstract][Full Text] [Related]
27. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
Gravina GL; Mancini A; Scarsella L; Colapietro A; Jitariuc A; Vitale F; Marampon F; Ricevuto E; Festuccia C
Tumour Biol; 2016 Jan; 37(1):341-51. PubMed ID: 26219891
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor.
Kanno Y; Zhao S; Yamashita N; Yanai K; Nemoto K; Inouye Y
J Toxicol Sci; 2015 Dec; 40(6):753-8. PubMed ID: 26558456
[TBL] [Abstract][Full Text] [Related]
29. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
30. Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells.
Varisli L; Gonen-Korkmaz C; Syed HM; Bogurcu N; Debelec-Butuner B; Erbaykent-Tepedelen B; Korkmaz KS
Mol Cell Endocrinol; 2012 Mar; 350(1):107-17. PubMed ID: 22155408
[TBL] [Abstract][Full Text] [Related]
31. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
Avgeris M; Stravodimos K; Scorilas A
Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
[TBL] [Abstract][Full Text] [Related]
32. Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway.
Spirina LV; Kovaleva IV; Usynin EA; Goorbunov AK; Kondakova IV
Asian Pac J Cancer Prev; 2020 Feb; 21(2):423-429. PubMed ID: 32102520
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
[TBL] [Abstract][Full Text] [Related]
34. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
Klokk TI; Kilander A; Xi Z; Waehre H; Risberg B; Danielsen HE; Saatcioglu F
Cancer Res; 2007 Jun; 67(11):5221-30. PubMed ID: 17545602
[TBL] [Abstract][Full Text] [Related]
35. Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer.
Miller KJ; Asim M
Cells; 2022 Mar; 11(6):. PubMed ID: 35326402
[TBL] [Abstract][Full Text] [Related]
36. PAGE4 positivity is associated with attenuated AR signaling and predicts patient survival in hormone-naive prostate cancer.
Sampson N; Ruiz C; Zenzmaier C; Bubendorf L; Berger P
Am J Pathol; 2012 Oct; 181(4):1443-54. PubMed ID: 22885105
[TBL] [Abstract][Full Text] [Related]
37. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
38. PI3K/mTOR signaling regulates prostatic branching morphogenesis.
Ghosh S; Lau H; Simons BW; Powell JD; Meyers DJ; De Marzo AM; Berman DM; Lotan TL
Dev Biol; 2011 Dec; 360(2):329-42. PubMed ID: 22015718
[TBL] [Abstract][Full Text] [Related]
39. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
[TBL] [Abstract][Full Text] [Related]
40. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
Takayama K; Misawa A; Suzuki T; Takagi K; Hayashizaki Y; Fujimura T; Homma Y; Takahashi S; Urano T; Inoue S
Nat Commun; 2015 Sep; 6():8219. PubMed ID: 26404510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
